Psycholeptics. Antipsychotics. Other antipsychotics. Aripiprazole.
The therapeutic effect of aripiprazole in the treatment of schizophrenia and bipolar I disorder is due to the combination of partial agonism for D2-dopamine and HT1A-serotonin receptors, as well as antagonism for 5-HT2A-serotonin receptors. Aripiprazole showed antagonistic properties in animal models of dopaminergic hyperactivity and agonistic properties in animal models of dopaminergic hypoactivity. Aripiprazole has a high binding affinity in vitro with D2- and D3-dopamine receptors, 5-HT1A- and 5-HT2A-serotonin receptors, as well as a moderate affinity with D4-dopamine receptors, 5-HT2C- and 5-HT7-serotonin, α-1-adrenergic and histamine H1-receptors. Aripiprazole also has a moderate affinity for serotonin reuptake sites and has no apparent affinity for muscarinic receptors. Interaction with receptors other than dopamine and serotonin subtypes may explain some other clinical effects of aripiprazole.
Treatment of schizophrenia in adults.
Treatment of moderate to severe manic episodes in bipolar I disorder, as well as for prevention of new manic episodes in adults who have previously experienced manic episodes and responded to the treatment with aripiprazole.
The medicine is intended for oral use. The tablet should be placed on the tongue, where it rapidly disperses in saliva. The tablet may be taken with or without fluid. It is difficult to remove the tablet from the mouth intact. Since the tablet is fragile, it should be taken immediately after opening the blister. Alternatively, one may disperse the tablet in water and drink the resulting suspension. Orodispersible tablets may be used as an alternative dosage form for patients who have difficulties with swallowing.